Gällande vårdprogram icke-epitelial äggstockscancer

Fastställt av Regionala cancercentrum i samverkan 2018-02-06.

20. Referenser

    1. Tavassoli FA, Devilee P, eds. World Health Organization classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press; 2003. ISBN 92-832-2412-4.
    2. Björkholm E, Lundell M, Gyftodimos A, Silfverswärd C. Dysgerminoma. The Radiumhemmet series 1927–1984. Cancer 1990; 44: 65–68.
    3. Williams SD. Gershenson DM. Horowitz CJ. Scully RE. Ovarian germcell tumours . In Hoskins WJ. Perez CA.Young RC. Principles and practice of Gynecologic Oncology. Philadelphia Lippincott-Raven Publishers, 1997: 987– 1001.
    4. Pauniaho SL, Salonen J, Helminen M, Vettenranta K, Heikinheimo M, Heikinheimo O. The incidences of malignant gonadal and extragonadal germ cell tumors in males and females: a population-based study covering over 40 years in Finland. Cancer Causes Control. 2012;23(12):1921-7.
    5. Sieh W, Sundquist K, Sundquist J, Winkleby MA, Crump C. Intrauterine factors and risk of nonepithelial ovarian cancers. Gynecol Oncol. 2014;133(2):293-7.
    6. Mayr D, Hirschmann A, Marlow S, Horvath C, Diebold J. Analysis of selected oncogenes (AKT1, FOS, BCL2L2, TGFbeta) on chromosome 14 in granulosa cell tumors (GCTs): a comprehensive study on 30 GCTs combining comparative genomic hybridization (CGH) and fluorescence-in situ-hybridization (FISH). Pathol Res Pract. 2008;204(11):823-30.
    7. Owens GE, Keri RA, Nilson JH. Ovulatory surges of human CG prevent hormone-induced granulosa cell tumor formation leading to the identification of tumor-associated changes in the transcriptome. Mol Endocrinol. 2002;16(6):1230-42.
    8. Shah SP, Kobel M, Senz J, Morin RD, Clarke BA, Wiegand KC, et al. Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med. 2009;360(26):2719-29.
    9. Kommoss S, Gilks CB, Penzel R, Herpel E, Mackenzie R, Huntsman D, et al. A current perspective on the pathological assessment of FOXL2 in adult-type granulosa cell tumours of the ovary. Histopathology. 2014;64(3):380-8.
    10. Dhillon VS, Shahid M, Husain SA. CpG methylation of the FHIT, FANCF, cyclin-D2, BRCA2 and RUNX3 genes in Granulosa cell tumors (GCTs) of ovarian origin. Mol Cancer. 2004;3:33.
    11. Kumar S, Shah JP, Bryant CS, Imudia AN, Cote ML, Ali-Fehmi R, et al. The prevalence and prognostic impact of lymph node metastasis in malignant germ cell tumors of the ovary. Gynecol Oncol. 2008;110(2):125-32.
    12. Low JJ, Perrin LC, Crandon AJ, Hacker NF. Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. A review of 74 cases. Cancer. 2000;89(2):391-8.
    13. Mahdi H, Swensen RE, Hanna R, Kumar S, Ali-Fehmi R, Semaan A, et al. Prognostic impact of lymphadenectomy in clinically early stage malignant germ cell tumour of the ovary. Br J Cancer. 2011;105(4):493-7.
    14. Bjorkholm E, Silfversward C. Granulosa- and theca-cell tumors. Incidence and occurrence of second primary tumors. Acta Radiol Oncol. 1980;19(3):161-7.
    15. Pectasides D, Pectasides E, Psyrri A. Granulosa cell tumor of the ovary. Cancer Treat Rev. 2008;34(1):1-12.
    16. Hammer A, Lauszus FF, Petersen AC. Ovarian granulosa cell tumor and increased risk of breast cancer. Acta Obstet Gynecol Scand. 2013;92(12):1422-5.
    17. Abu-Rustum NR, Restivo A, Ivy J, Soslow R, Sabbatini P, Sonoda Y, et al. Retroperitoneal nodal metastasis in primary and recurrent granulosa cell tumors of the ovary. Gynecol Oncol. 2006;103(1):31-4.
    18. Ayhan A, Salman MC, Velipasaoglu M, Sakinci M, Yuce K. Prognostic factors in adult granulosa cell tumors of the ovary: a retrospective analysis of 80 cases. J Gynecol Oncol. 2009;20(3):158-63.
    19. Brown J, Sood AK, Deavers MT, Milojevic L, Gershenson DM. Patterns of metastasis in sex cord-stromal tumors of the ovary: can routine staging lymphadenectomy be omitted? Gynecol Oncol. 2009;113(1):86-90.
    20. Park JY, Jin KL, Kim DY, Kim JH, Kim YM, Kim KR, et al. Surgical staging and adjuvant chemotherapy in the management of patients with adult granulosa cell tumors of the ovary. Gynecol Oncol. 2012;125(1):80-6.
    21. Thrall MM, Paley P, Pizer E, Garcia R, Goff BA. Patterns of spread and recurrence of sex cord-stromal tumors of the ovary. Gynecol Oncol. 2011;122(2):242-5.
    22. Colombo N, Peiretti M, Castiglione M, Group EGW. Non-epithelial ovarian cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20 Suppl 4:24-6.
    23. Reed N, Millan D, Verheijen R, Castiglione M, Group EGW. Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v31-6.
    24. Cole LA, Sutton JM. HCG tests in the management of gestational trophoblastic diseases. Clin Obstet Gynecol. 2003;46(3):523-40.
    25. Stenman UH. Testicular cancer: the perfect paradigm for marker combinations. Scand J Clin Lab Invest. 2005;65(3):181-8.
    26. Olofsson SE, Tandstad T, Jerkeman M, Dahl O, Stahl O, Klepp O, et al. Population-based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: a report from the Swedish-Norwegian Testicular Cancer Group. J Clin Oncol. 2011;29(15):2032-9.
    27. Robertson DM, Cahir N, Burger HG, Mamers P, McCloud PI, Pettersson K, et al. Combined inhibin and CA125 assays in the detection of ovarian cancer. Clin Chem. 1999;45(5):651-8.
    28. Lane AH, Lee MM, Fuller AF, Jr., Kehas DJ, Donahoe PK, MacLaughlin DT. Diagnostic utility of Mullerian inhibiting substance determination in patients with primary and recurrent granulosa cell tumors. Gynecol Oncol. 1999;73(1):51-5.
    29. Long WQ, Ranchin V, Pautier P, Belville C, Denizot P, Cailla H, et al. Detection of minimal levels of serum anti-Mullerian hormone during follow-up of patients with ovarian granulosa cell tumor by means of a highly sensitive enzyme-linked immunosorbent assay. J Clin Endocrinol Metab. 2000;85(2):540-4.
    30. Rey RA, Lhomme C, Marcillac I, Lahlou N, Duvillard P, Josso N, et al. Antimullerian hormone as a serum marker of granulosa cell tumorsof the ovary: comparative study with serum alpha-inhibin and estradiol. Am J Obstet Gynecol. 1996;174(3):958-65.
    31. Petraglia F, Luisi S, Pautier P, Sabourin JC, Rey R, Lhomme C, et al. Inhibin B is the major form of inhibin/activin family secreted by granulosa cell tumors. J Clin Endocrinol Metab. 1998;83(3):1029-32.
    32. Jobling T, Mamers P, Healy DL, MacLachlan V, Burger HG, Quinn M, et al. A prospective study of inhibin in granulosa cell tumors of the ovary. Gynecol Oncol. 1994;55(2):285-9.
    33. Gustafson ML, Lee MM, Scully RE, Moncure AC, Hirakawa T, Goodman A, et al. Mullerian inhibiting substance as a marker for ovarian sex-cord tumor. N Engl J Med. 1992;326(7):466-71.
    34. Geerts I, Vergote I, Neven P, Billen J. The role of inhibins B and antimullerian hormone for diagnosis and follow-up of granulosa cell tumors. Int J Gynecol Cancer. 2009;19(5):847-55.
    35. Ray-Coquard I, Weber B, Lotz JP, Tournigand C, Provencal J, Mayeur D, et al. Management of rare ovarian cancers: the experience of the French website "Observatory for rare malignant tumours of the ovaries" by the GINECO group: interim analysis of the first 100 patients. Gynecol Oncol. 2010;119(1):53-9.
    36. Mangili G, Sigismondi C, Gadducci A, Cormio G, Scollo P, Tateo S, et al. Outcome and risk factors for recurrence in malignant ovarian germ cell tumors: a MITO-9 retrospective study. Int J Gynecol Cancer. 2011;21(8):1414-21.
    37. Park JY, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT, et al. Outcomes of Surgery Alone and Surveillance Strategy in Young Women With Stage I Malignant Ovarian Germ Cell Tumors. Int J Gynecol Cancer. 2016;26(5):859-64.
    38. Kempf E, Desamericq G, Vieites B, Diaz-Padilla I, Calvo E, Estevez P, et al. Clinical and pathologic features of patients with non-epithelial ovarian cancer: retrospective analysis of a single institution 15-year experience. Clin Transl Oncol. 2016.
    39. Billmire D, Vinocur C, Rescorla F, Cushing B, London W, Schlatter M, et al. Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study. J Pediatr Surg. 2004;39(3):424-9; discussion -9.
    40. Gershenson DM. Current advances in the management of malignant germ cell and sex cord-stromal tumors of the ovary. Gynecol Oncol. 2012;125(3):515-7.
    41. Williams SD, Blessing JA, Moore DH, Homesley HD, Adcock L. Cisplatin, vinblastine, and bleomycin in advanced and recurrent ovarian germ-cell tumors. A trial of the Gynecologic Oncology Group. Ann Intern Med. 1989;111(1):22-7.
    42. Lu KH, Gershenson DM. Update on the management of ovarian germ cell tumors. J Reprod Med. 2005;50(6):417-25.
    43. Culine S, Kattan J, Lhomme C, Duvillard P, Michel G, Castaigne D, et al. A phase II study of high-dose cisplatin, vinblastine, bleomycin, and etoposide (PVeBV regimen) in malignant nondysgerminomatous germ-cell tumors of the ovary. Gynecol Oncol. 1994;54(1):47-53.
    44. Cushing B, Giller R, Cullen JW, Marina NM, Lauer SJ, Olson TA, et al. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882. J Clin Oncol. 2004;22(13):2691-700.
    45. Dimopoulos MA, Papadopoulou M, Andreopoulou E, Papadimitriou C, Pavlidis N, Aravantinos G, et al. Favorable outcome of ovarian germ cell malignancies treated with cisplatin or carboplatin-based chemotherapy: a Hellenic Cooperative Oncology Group study. Gynecol Oncol. 1998;70(1):70-4.
    46. Brown J, Friedlander M, Backes FJ, Harter P, O'Connor DM, de la Motte Rouge T, et al. Gynecologic Cancer Intergroup (GCIG) consensus review for ovarian germ cell tumors. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S48-54.
    47. Culine S, Droz JP. Comparative tolerability of chemotherapy regimens for germ cell cancer. Drug Saf. 2000;22(5):373-88.
    48. Kawai K, Akaza H. Current status of chemotherapy in risk-adapted management for metastatic testicular germ cell cancer. Cancer Sci. 2010;101(1):22-8.
    49. Solheim O, Trope CG, Rokkones E, Kaern J, Paulsen T, Salvesen HB, et al. Fertility and gonadal function after adjuvant therapy in women diagnosed with a malignant ovarian germ cell tumor (MOGCT) during the "cisplatin era". Gynecol Oncol. 2015;136(2):224-9.
    50. Matei D, Miller AM, Monahan P, Gershenson D, Zhao Q, Cella D, et al. Chronic physical effects and health care utilization in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group study. J Clin Oncol. 2009;27(25):4142-9.
    51. Travis LB, Andersson M, Gospodarowicz M, van Leeuwen FE, Bergfeldt K, Lynch CF, et al. Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst. 2000;92(14):1165-71.
    52. Dark GG, Bower M, Newlands ES, Paradinas F, Rustin GJ. Surveillance policy for stage I ovarian germ cell tumors. J Clin Oncol. 1997;15(2):620-4.
    53. Williams SD. Ovarian germ cell tumors: an update. Semin Oncol. 1998;25(3):407-13.
    54. Mangili G, Sigismondi C, Lorusso D, Cormio G, Scollo P, Vigano R, et al. Is surgical restaging indicated in apparent stage IA pure ovarian dysgerminoma? The MITO group retrospective experience. Gynecol Oncol. 2011;121(2):280-4.
    55. Gershenson DM, Morris M, Cangir A, Kavanagh JJ, Stringer CA, Edwards CL, et al. Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin. J Clin Oncol. 1990;8(4):715-20.
    56. Gershenson DM. Management of ovarian germ cell tumors. J Clin Oncol. 2007;25(20):2938-43.
    57. Culine S, Lhomme C, Kattan J, Michel G, Duvillard P, Droz JP. Cisplatin-based chemotherapy in the management of germ cell tumors of the ovary: The Institut Gustave Roussy Experience. Gynecol Oncol. 1997;64(1):160-5.
    58. Bonazzi C, Peccatori F, Colombo N, Lucchini V, Cantu MG, Mangioni C. Pure ovarian immature teratoma, a unique and curable disease: 10 years' experience of 32 prospectively treated patients. Obstet Gynecol. 1994;84(4):598-604.
    59. Gershenson DM, Frazier AL. Conundrums in the management of malignant ovarian germ cell tumors: Toward lessening acute morbidity and late effects of treatment. Gynecol Oncol. 2016;143(2):428-32.
    60. Andre F, Fizazi K, Culine S, Droz J, Taupin P, Lhomme C, et al. The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients. Eur J Cancer. 2000;36(11):1389-94.
    61. Manchana T, Ittiwut C, Mutirangura A, Kavanagh JJ. Targeted therapies for rare gynaecological cancers. Lancet Oncol. 2010;11(7):685-93.
    62. Talukdar S, Kumar S, Bhatla N, Mathur S, Thulkar S, Kumar L. Neo-adjuvant chemotherapy in the treatment of advanced malignant germ cell tumors of ovary. Gynecol Oncol. 2014;132(1):28-32.
    63. Chan JK, Zhang M, Kaleb V, Loizzi V, Benjamin J, Vasilev S, et al. Prognostic factors responsible for survival in sex cord stromal tumors of the ovary--a multivariate analysis. Gynecol Oncol. 2005;96(1):204-9.
    64. Lauszus FF, Petersen AC, Neumann G, Cleemann L, Rosgaard A, Jorgensen A, et al. Less extensive surgery compared to extensive surgery: survival seems similar in young women with adult ovarian granulosa cell tumor. Eur J Obstet Gynecol Reprod Biol. 2014;177:61-6.
    65. Teoh D, Freedman R, Soliman PT. Nearly 30 Years of Treatment for Recurrent Granulosa Cell Tumor of the Ovary: A Case Report and Review of the Literature. Case Rep Oncol. 2010;3(1):14-8.
    66. Homesley HD, Bundy BN, Hurteau JA, Roth LM. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: A Gynecologic Oncology Group study. Gynecol Oncol. 1999;72(2):131-7.
    67. Brown J, Shvartsman HS, Deavers MT, Ramondetta LM, Burke TW, Munsell MF, et al. The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors. Gynecol Oncol. 2005;97(2):489-96.
    68. Wolf JK, Mullen J, Eifel PJ, Burke TW, Levenback C, Gershenson DM. Radiation treatment of advanced or recurrent granulosa cell tumor of the ovary. Gynecol Oncol. 1999;73(1):35-41.
    69. Hauspy J, Beiner ME, Harley I, Rosen B, Murphy J, Chapman W, et al. Role of adjuvant radiotherapy in granulosa cell tumors of the ovary. Int J Radiat Oncol Biol Phys. 2011;79(3):770-4.
    70. Tao X, Sood AK, Deavers MT, Schmeler KM, Nick AM, Coleman RL, et al. Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors. Gynecol Oncol. 2009;114(3):431-6.
    71. Schmidt M, Kammerer U, Segerer S, Cramer A, Kohrenhagen N, Dietl J, et al. Glucose metabolism and angiogenesis in granulosa cell tumors of the ovary: activation of Akt, expression of M2PK, TKTL1 and VEGF. Eur J Obstet Gynecol Reprod Biol. 2008;139(1):72-8.
    72. Kim JH, Kim YH, Kim HM, Park HO, Ha NC, Kim TH, et al. FOXL2 posttranslational modifications mediated by GSK3beta determine the growth of granulosa cell tumours. Nat Commun. 2014;5:2936.
    73. Suh DS, Oh HK, Kim JH, Park S, Shin E, Lee K, et al. Identification and Validation of Differential Phosphorylation Sites of the Nuclear FOXL2 Protein as Potential Novel Biomarkers for Adult-Type Granulosa Cell Tumors. J Proteome Res. 2015;14(6):2446-56.
    74. Raspagliesi F, Martinelli F, Grijuela B, Guadalupi V. Third-line chemotherapy with tyrosine kinase inhibitor (imatinib mesylate) in recurrent ovarian granulosa cell tumor: case report. J Obstet Gynaecol Res. 2011;37(12):1864-7.
    75. Ioffe OB, Simsir A, Silverberg. Pathology. In: Berek JS, Hacker NF, eds. Practical Gynecologic Oncology. Philadelphia: Lippincott-Williams & Wilkins, 2005: 163 242.
    76. Gui T, Cao D, Shen K, Yang J, Zhang Y, Yu Q, et al. A clinicopathological analysis of 40 cases of ovarian Sertoli-Leydig cell tumors. Gynecol Oncol. 2012;127(2):384-9.
    77. Sigismondi C, Gadducci A, Lorusso D, Candiani M, Breda E, Raspagliesi F, et al. Ovarian Sertoli-Leydig cell tumors. a retrospective MITO study. Gynecol Oncol. 2012;125(3):673-6.
    78. Schultz KA, Pacheco MC, Yang J, Williams GM, Messinger Y, Hill DA, et al. Ovarian sex cord-stromal tumors, pleuropulmonary blastoma and DICER1 mutations: a report from the International Pleuropulmonary Blastoma Registry. Gynecol Oncol. 2011;122(2):246-50.
    79. Reed NS, Pautier P, Avall-Lundqvist E, Choi CH, du Bois A, Friedlander M, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian small cell cancers. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S30-4.
    80. Jelinic P, Schlappe BA, Conlon N, Tseng J, Olvera N, Dao F, et al. Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic type. Mod Pathol. 2016;29(1):60-6.
    81. Woopen H, Sehouli J, Pietzner K, Darb-Esfahani S, Braicu EI, Fotopoulou C. Clinical experience of young patients with small cell ovarian carcinoma of the hypercalcemic type (OSCCHT). Eur J Obstet Gynecol Reprod Biol. 2012;165(2):313-7.
    82. Harrison ML, Hoskins P, du Bois A, Quinn M, Rustin GJ, Ledermann JA, et al. Small cell of the ovary, hypercalcemic type -- analysis of combined experience and recommendation for management. A GCIG study. Gynecol Oncol. 2006;100(2):233-8.
    83. Callegaro-Filho D, Gershenson DM, Nick AM, Munsell MF, Ramirez PT, Eifel PJ, et al. Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT): A review of 47 cases. Gynecol Oncol. 2016;140(1):53-7.
    84. Tsolakidis D, Papanikolaou A, Ktenidis K, Pervana S. Primary ovarian small cell carcinoma of pulmonary type with enlarged paraaortic lymph node masses: a case report and review of the literature. Eur J Gynaecol Oncol. 2012;33(3):312-5.
    85. Shakuntala PN, Uma Devi K, Shobha K, Bafna UD, Geetashree M. Pure large cell neuroendocrine carcinoma of ovary: a rare clinical entity and review of literature. Case Rep Oncol Med. 2012;2012:120727.
    86. Voutsadakis IA. Large cell neuroendocrine carcinoma of the ovary: A pathologic entity in search of clinical identity. World J Clin Oncol. 2014;5(2):36-8.
    87. Lindboe CF. Large cell neuroendocrine carcinoma of the ovary. APMIS. 2007;115(2):169-76.
    88. Asada K, Kawana K, Teshima S, Saito A, Kawabata M, Fujii T. Poor prognosis of ovarian cancer with large cell neuroendocrine carcinoma: case report and review of published works. J Obstet Gynaecol Res. 2014;40(3):869-72.
    89. Tsuji T, Togami S, Shintomo N, Fukamachi N, Douchi T, Taguchi S. Ovarian large cell neuroendocrine carcinoma. J Obstet Gynaecol Res. 2008;34(4 Pt 2):726-30.
    90. Shakuntala P, Umadevi K, Usha A, Abhilasha N, Bafna U. Primary ovarian adenosarcoma with elevated Ca-125 levels and normal ascitic fluid cytology: a case report and review of literature. Ecancermedicalscience. 2012;6:284.
    91. Rekhi B, Deodhar KK, Maheshwari A, Menon S, Kerkar R, Bajpai J, et al. Clinicopathological spectrum of 19 adenosarcomas of female genital tract, including uncommon clinical associations and immunohistochemical profile, reviewed at a single institution. Indian J Pathol Microbiol. 2012;55(3):326-32.
    92. Eichhorn JH, Young RH, Clement PB, Scully RE. Mesodermal (mullerian) adenosarcoma of the ovary: a clinicopathologic analysis of 40 cases and a review of the literature. Am J Surg Pathol. 2002;26(10):1243-58.
    93. Kahyaoglu S, Kahyaoglu I, Sirvan L, Sengul I, Timur H, Mollamahmutoglu L. Female Adnexial Tumor of Probable Wolffian Origin (FATWO) without Ki-67 Expression Reflecting Low Malignant Potential in a 55-Year-Old Woman. Eurasian J Med. 2012;44(3):172-5.
    94. Berton-Rigaud D, Devouassoux-Shisheboran M, Ledermann JA, Leitao MM, Powell MA, Poveda A, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S55-60.
    95. Shylasree TS, Bryant A, Athavale R. Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma. Cochrane Database Syst Rev. 2013(2):CD006246.
    96. Rauh-Hain JA, Shoni M, Schorge JO, Goodman A, Horowitz NS, del Carmen MG. Prognostic determinants in patients with uterine and ovarian carcinosarcoma. J Reprod Med. 2013;58(7-8):297-304.
    97. George EM, Herzog TJ, Neugut AI, Lu YS, Burke WM, Lewin SN, et al. Carcinosarcoma of the ovary: natural history, patterns of treatment, and outcome. Gynecol Oncol. 2013;131(1):42-5.
    98. Rauh-Hain JA, Growdon WB, Rodriguez N, Goodman AK, Boruta DM, 2nd, Schorge JO, et al. Carcinosarcoma of the ovary: a case-control study. Gynecol Oncol. 2011;121(3):477-81.
    99. del Carmen MG, Birrer M, Schorge JO. Carcinosarcoma of the ovary: a review of the literature. Gynecol Oncol. 2012;125(1):271-7.
    100. Lee IH, Choi CH, Hong DG, Song JY, Kim YJ, Kim KT, et al. Clinicopathologic characteristics of granulosa cell tumors of the ovary: a multicenter retrospective study. J Gynecol Oncol. 2011;22(3):188-95.
    101. Shim SH, Lee SJ, Kim DY, Kim J, Kim SN, Kang SB, et al. A Long-term follow-up study of 91 cases with ovarian granulosa cell tumors. Anticancer Res. 2014;34(2):1001-10.
    102. Lauszus FF, Petersen AC, Greisen J, Jakobsen A. Granulosa cell tumor of the ovary: a population-based study of 37 women with stage I disease. Gynecol Oncol. 2001;81(3):456-60.
    103. Sun HD, Lin H, Jao MS, Wang KL, Liou WS, Hung YC, et al. A long-term follow-up study of 176 cases with adult-type ovarian granulosa cell tumors. Gynecol Oncol. 2012;124(2):244-9.
    104. Fox H. Pathologic prognostic factors in early stage adult-type granulosa cell tumors of the ovary. Int J Gynecol Cancer. 2003;13(1):1-4.
    105. Zhang M, Cheung MK, Shin JY, Kapp DS, Husain A, Teng NN, et al. Prognostic factors responsible for survival in sex cord stromal tumors of the ovary--an analysis of 376 women. Gynecol Oncol. 2007;104(2):396-400.
    106. Koulouris CR, Penson RT. Ovarian stromal and germ cell tumors. Semin Oncol. 2009;36(2):126-36.
    107. Colombo N, Peiretti M, Garbi A, Carinelli S, Marini C, Sessa C, et al. Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii20-6.
    108. Zola P, Macchi C, Cibula D, Colombo N, Kimmig R, Maggino T, et al. Follow-up in Gynecological Malignancies: A State of Art. Int J Gynecol Cancer. 2015;25(7):1151-64.
    109. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Ovarian Cancer Including Fallopian Tube Cancer and Primaty Peritoneal Cancer. 2017.
    110. Royal College of Obstetricians and Gynaecologists. Management of Female Malignant Ovarian Germ Cell Tumours (Scientific Impact Paper No.52). 2016.
    111. Forstner R, Thomassin-Naggara I, Cunha TM, Kinkel K, Masselli G, Kubik-Huch R, et al. ESUR recommendations for MR imaging of the sonographically indeterminate adnexal mass: an update. Eur Radiol. 2017;27(6):2248-57.
    112. Murugaesu N, Schmid P, Dancey G, Agarwal R, Holden L, McNeish I, et al. Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment. J Clin Oncol. 2006;24(30):4862-6.
    113. Mangili G, Ottolina J, Gadducci A, Giorda G, Breda E, Savarese A, et al. Long-term follow-up is crucial after treatment for granulosa cell tumours of the ovary. Br J Cancer. 2013;109(1):29-34.
    114. Taira Y, Hirakawa M, Nagayama C, Ikemiyagi K, Touma T, Tokashiki M. Successful treatment of adult-type granulosa cell tumor of the ovary by palliative radiotherapy. J Obstet Gynaecol Res. 2012;38(2):461-5.
    115. Alhilli MM, Long HJ, Podratz KC, Bakkum-Gamez JN. Aromatase inhibitors in the treatment of recurrent ovarian granulosa cell tumors: brief report and review of the literature. J Obstet Gynaecol Res. 2012;38(1):340-4.
    116. Korach J, Perri T, Beiner M, Davidzon T, Fridman E, Ben-Baruch G. Promising effect of aromatase inhibitors on recurrent granulosa cell tumors. Int J Gynecol Cancer. 2009;19(5):830-3.
    117. Hardy RD, Bell JG, Nicely CJ, Reid GC. Hormonal treatment of a recurrent granulosa cell tumor of the ovary: case report and review of the literature. Gynecol Oncol. 2005;96(3):865-9.
    118. Gershenson DM, Miller AM, Champion VL, Monahan PO, Zhao Q, Cella D, et al. Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(19):2792-7.
    119. Singh P, Oehler MK. Hormone replacement after gynaecological cancer. Maturitas. 2010;65(3):190-7.
    120. Geetha P, Nair MK. Granulosa cell tumours of the ovary. Aust N Z J Obstet Gynaecol. 2010;50(3):216-20.
    121. Wells M, Macmillan M, Raab G, MacBride S, Bell N, MacKinnon K, et al. Does aqueous or sucralfate cream affect the severity of erythematous radiation skin reactions? A randomised controlled trial. Radiother Oncol. 2004;73(2):153-62.
    122. Iwakawa M, Noda S, Yamada S, Yamamoto N, Miyazawa Y, Yamazaki H, et al. Analysis of non-genetic risk factors for adverse skin reactions to radiotherapy among 284 breast cancer patients. Breast Cancer. 2006;13(3):300-7.
    123. Jagsi R, Griffith KA, Koelling T, Roberts R, Pierce LJ. Rates of myocardial infarction and coronary artery disease and risk factors in patients treated with radiation therapy for early-stage breast cancer. Cancer. 2007;109(4):650-7.
    124. Kaufman EL, Jacobson JS, Hershman DL, Desai M, Neugut AI. Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer. J Clin Oncol. 2008;26(3):392-8.
    125. Macdonald G, Kondor N, Yousefi V, Green A, Wong F, Aquino-Parsons C. Reduction of carboxyhaemoglobin levels in the venous blood of cigarette smokers following the administration of carbogen. Radiother Oncol. 2004;73(3):367-71.
    126. Sharp L, Johansson H, Hatschek T, Bergenmar M. Smoking as an independent risk factor for severe skin reactions due to adjuvant radiotherapy for breast cancer. Breast. 2013;22(5):634-8.
    127. Peterson C. [Natural remedies--self care at your own risk! Danger of unknown adverse effects and interactions with "common" medications]. Lakartidningen. 2005;102(44):3200-1.
    128. Malekzadeh F, Rose C, Ingvar C, Jernstrom H. [Natural remedies and hormone preparations--potential risk for breast cancer patients. A study surveys the use of agents which possibly counteract with the treatment]. Lakartidningen. 2005;102(44):3226-8, 30-1.
    129. Tonnesen H, Nielsen PR, Lauritzen JB, Moller AM. Smoking and alcohol intervention before surgery: evidence for best practice. Br J Anaesth. 2009;102(3):297-306.
    130. Nath B, Li Y, Carroll JE, Szabo G, Tseng JF, Shah SA. Alcohol exposure as a risk factor for adverse outcomes in elective surgery. J Gastrointest Surg. 2010;14(11):1732-41.
    131. Bradley KA, Rubinsky AD, Sun H, Bryson CL, Bishop MJ, Blough DK, et al. Alcohol screening and risk of postoperative complications in male VA patients undergoing major non-cardiac surgery. J Gen Intern Med. 2011;26(2):162-9.